Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
3.165
+0.075 (2.43%)
May 20, 2026, 11:19 AM EDT - Market open
Lantern Pharma Employees
Lantern Pharma had 16 employees as of December 31, 2025. The number of employees decreased by 8 or -33.33% compared to the previous year.
Employees
16
Change (1Y)
-8
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$994,489
Market Cap
35.48M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | -8 | -33.33% | 16 | 0 |
| Dec 31, 2024 | 24 | 3 | 14.29% | 24 | 0 |
| Dec 31, 2023 | 21 | -2 | -8.70% | 21 | 0 |
| Dec 31, 2022 | 23 | 7 | 43.75% | 22 | 1 |
| Dec 31, 2021 | 16 | 1 | 6.67% | 14 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Aligos Therapeutics | 82 |
| Evaxion | 46 |
| NextCure | 40 |
| Boundless Bio | 28 |
| Actinium Pharmaceuticals | 25 |
| Veru Inc. | 20 |
| RenovoRx | 17 |
LTRN News
- 1 day ago - Lantern receives successful response to Type C meeting from FDA on LP-300 - TheFly
- 1 day ago - Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC - Business Wire
- 4 days ago - Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates - Business Wire
- 4 days ago - Lantern Pharma Earnings release: Q1 2026 - Filings
- 4 days ago - Lantern Pharma Quarterly report: Q1 2026 - Filings
- 5 days ago - Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor - Business Wire
- 6 days ago - Lantern Pharma prices 2.14M shares at $2.06 in registered direct offering - TheFly
- 7 days ago - Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor - Business Wire